On Demand Webinar: The medicolegal implications of prescribing for asthma
Please note: the Q&A feature is not available for on demand webinars, and the PCRS Membership offer is only available to those who attended the live webinar.
Beverley Bostock RGN MSc MA QN, Advanced Nurse Practitioner and Independent Training Consultant, Editor in Chief of the Practice Nurse Journal, PCRS Policy Forum member, Asthma Lead for the Association of Respiratory Nurse Specialists, and an Expert Witness in clinical negligence
Darush Attar-Zadeh, Pharmacist, PCRS Conference Organising Committee Co-Chair, Behaviour Change Specialist and International Respiratory Trainer
Handout: Resources from the webinar
- short-acting bronchodilator prescribing – general advice
- short-acting bronchodilator prescribing during the pandemic
- 'just in case' prescribing
- the impact of COVID-19 on prescribing and dispensing habits – lessons learned
The views expressed by speakers or other thirds parties in this series of ARC webinars are those of the speaker or third party and not necessarily of PCRS. Whilst every effort has been made to ensure the information and guidance is accurate, it is impossible to predict all the circumstances in which it may be used and PCRS assumes no responsibility or liability for any errors or omissions made in the content of these webinars. All webinars delivered by PCRS are provided for informational and educational purposes only. Their content should not be considered applicable to all situations or patients. Neither do the contents negate the requirement for comprehensive assessment of patients or the importance of discussing the benefits and risks of intervention with patients, their families and caregivers. Where links are provided to other sites and resources of third parties, these links are provided for your information only. PCRS neither endorses not accepts responsibility for the contents of third party sites or resources. For more information see our Website Terms and Conditions.
|The Asthma Right Care initiative was originated by the IPCRG with funding from AstraZeneca internationally. The adaptation of materials by PCRS for use in the UK has been funded by AstraZeneca UK Limited.|